Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The bio...

We propose that psoriasis is a sequela of streptococcal infection similar to acute rheumatic fever (ARF). This hypothesis arises from many different lines of evidence: a markedly elevated serum anti-streptococcal antibody is present in plaque psoriasis. However, cultures are routinely negative in psoriasis because the Group A Streptococcus pyogenes “hides” inside cells and inside biofilms and i...

OBJECTIVE To describe practice patterns for care of Canadian patients with moderate to severe plaque psoriasis. DESIGN Online survey of a consumer panel. SETTING Participants were drawn from a population-wide Canadian consumer database. PARTICIPANTS To be eligible to participate, respondents had to have been diagnosed with plaque psoriasis within the past 5 years, and to have had body sur...

BACKGROUND There is little information concerning the costs of psoriasis and patients' quality of life (QoL) in Germany. OBJECTIVE To obtain data on the annual costs and QoL(to follow in a further publication) of patients with moderate to severe plaque psoriasis. METHODS Between October 2003 and February 2004, six office-based dermatologists and eight dermatology outpatient departments retr...

OBJECTIVE To estimate the prevalence of chronic kidney disease (CKD) and evaluate renal function in patients with moderate-to-severe chronic plaque psoriasis treated with etanercept (an anti-tumour necrosis factor-α drug). METHODS This retrospective cohort study included patients with moderate-to-severe chronic plaque psoriasis. Kidney function was evaluated using estimated glomerular filtrat...

Tofacitinib is an oral Janus kinase inhibitor that is being investigated for psoriasis and psoriatic arthritis. Japanese patients aged 20 years or more with moderate to severe plaque psoriasis and/or psoriatic arthritis were double-blindly randomized 1:1 to tofacitinib 5 or 10 mg b.i.d. for 16 weeks, open-label 10 mg b.i.d. for 4 weeks, then variable 5 or 10 mg b.i.d. to Week 52. Primary end-po...

INTRODUCTION: Plaque-type psoriasis affecting the nails, scalp, hands or feet can often be difficult to treat; for example, topical treatments and phototherapy may not penetrate the nail plate or scalp. The objective of this large, international, multicentre study was to investigate the efficacy of efalizumab in a Latin American population of adult patients with moderate-to-severe chronic plaqu...

Psoriasis is an autoimmune and recurrent chronic inflammatory skin disease. About 1-3% of the world wide populations are affected. The characteristic features are hyperprolifration of keratinocytes leading to redness, thickening and scaling of epidermis followed with itching and appearance of the lesions which in most cases bother the patients medically and psychologically. Psoriasis is symptom...

Psoriasis is defined as a common, genetically determined, inflammatory and proliferative disease of skin, the most characteristic lesions consisting of chronic, sharply demarcated, dull-red, scaly plaques, particularly on the extensor prominences and in the scalp. The prevalence of Psoriasis in Western Europe and Scandinavia is between about 1.5 and 3%. The low prevalence of Psoriasis in orient...

Psoriasis is a chronic inflammatory papulo-squamous disorder of skin characterized by sharply defined erythematous-squamous lesion varying from pinpoint to large plaque, affecting 1-3% population worldwide. well known for its course remission and exacerbation. Here we report case 14-year-oldmale 42 kg weight, rotund physique child, diagnosed as Guttate psoriasis, psoriasis can be closely correl...